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Objective: Long-term mechanical circulatory support as a bridge-to-
transplantation procedure and bridge to recovery is of increasing
importance. The implantable left ventricular assist devices, Novacor
N100 left ventricular assist system (Baxter Healthcare Corporation,
Berkeley, Calif) and TCI HeartMate vented electric left ventricular
assist system (Thermo Cardiosystems Inc, Woburn, Mass), have proved
to be efficient devices in bridge-to-transplantation settings and for pro-
longed support. The two systems were compared with regard to relia-
bility and morbidity. Methods: Between October 1996 and March 1998, a
prospective, single-center study was done that included 40 patients, 20
of whom were treated with the Novacor system and 20 of whom were
treated with the HeartMate device. The diseases were mainly dilated
cardiomyopathy (13/9) and ischemic cardiomyopathy (6/10). There were
no statistically significant differences between the two groups regarding
age, sex, preoperative clinical blood chemistry values, hemodynamic
data, or risk factors. Results: There were no statistically significant dif-
ferences between the two groups with regard to postoperative hemody-
namics, organ recovery, out-of-hospital support, and survival to heart
transplantation. Mean duration of support was 235.3 ± 210 days for the
Novacor group and 174.6 ± 175 days for the HeartMate group and mean
out-of-hospital support was 241 ± 179 days and 166 ± 152 days for the
two groups, respectively. Neurologic complications occurred significant-
ly more often among the Novacor group, whereas the HeartMate group
had a higher prevalence of infections and technical problems, which was
statistically significant. Survival to transplantation was 65% for the
Novacor group and 60% for the HeartMate group. Conclusions: Most
patients had organ recovery with left ventricular assist system support,
and a considerable number of patients in both groups underwent trans-
plantation. However, both devices need revision to address the current
problems, that is, thromboembolism for the Novacor device and infec-
tion and reliability for the HeartMate device. (J Thorac Cardiovasc
Surg 2000;119:581-7)
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The number of patients with heart failure is steadilyincreasing with an estimated 400,000 new cases
recorded annually in the United States.1 Modern med-
ical treatments with angiotensin-converting enzyme
inhibitors and β-blocking agents have failed to improve
the clinical performance of these patients to an accept-
able level. Ninety percent of lethal outcomes are due to
cardiac causes. Heart transplantation currently is the
only accepted therapy for end-stage heart failure; how-
ever, it is restricted by the general shortage of donor
organs, which results in prolonged waiting times. In
addition to the bridge-to-transplantation application,
the option of mechanical circulatory support applied as
a bridge to recovery is getting more and more impor-
tant. Apart from the nonimplantable Thoratec ventricu-
lar assist device (Thoratec Laboratories Corporation,
Pleasanton, Calif), the implantable left ventricular
assist devices (LVADs) are the Novacor N100 left ven-
tricular assist system (LVAS) (Baxter Healthcare
Corporation, Berkeley, Calif) and the TCI HeartMate
vented electric (VE) LVAS (Thermo Cardiosystems
Inc, Woburn, Mass), both of which have obtained Food
and Drug Administration approval as bridge-to-trans-
plantation devices. Many trials have proved the effica-
cy of both devices in bridge-to-transplantation settings
and for long-term support. However, there has been no
investigation so far comparing the two systems with
regard to reliability and morbidity on the basis of organ
function during support, and this constitutes the aim of
the present study.
Patients and methods
In a prospective, single-center study done between October
1996 and March 1998, we compared the Novacor and the
HeartMate devices in terms of morbidity and reliability after
implantation. End points of the study were heart transplanta-
tion or death of the patient. After study approval by the local
ethics committee was obtained, patients requiring mechanical
left ventricular support as a bridge to transplantation alterna-
tively received either the Novacor LVAS or HeartMate VE
LVAS device. After patients were accepted into the study, the
relevant data were obtained on a daily basis from data sheets.
Forty patients were included in the study, 20 of whom
received the Novacor system (19 Novacor, 1 Novacor plus
Thoratec ventricular assist device) and 20 of whom received
the HeartMate system (19 HeartMate, 1 HeartMate plus
Medos right ventricular assist device [Medos; Hamburg,
Germany]). Both subsets consisted of 19 men and 1 woman
each, with mean ages of 55.7 ± 11 years for the Novacor
group and 56.3 ± 11 years for the HeartMate group. The caus-
es of heart failure in both collectives are summarized in Table
I. There were no statistically significant differences between
patients in the Novacor and HeartMate groups as to preoper-
ative laboratory parameters and hemodynamic data (Tables II
and III) and preoperative risk factors (Table IV).
Implantation procedures were done by the same surgical
team in both the Novacor and HeartMate groups. Both
devices are placed into a preperitoneal pocket and share the
same inflow and outflow cannulation. Furthermore, the same
protocols were applied with regard to antibiotic and infection
management strategies and intensive care unit and regular
ward management protocols. Anticoagulation regimens dif-
fered between the groups according to our previous experi-
ences and the recommendations established by the manufac-
turers of the devices. In the first 24 hours after the operation
the patients (both groups) received no anticoagulants.
Thereafter, therapy was started with heparin according to the
activated clotting time (1.5 × initial value). After removal of
chest drains patients in the Novacor group received warfarin
sodium (Coumadin) (dosage according to international nor-
malized ratio 2.5-3.5). Two weeks after the operation, both
patient groups received aspirin, 1 mg/kg of body weight.
Patients in both groups were discharged from the hospital
with the device in place if they fulfilled our selection criteria
for out-of-hospital support, which have been published else-
where.2 All patients followed the same home-management
protocol, which included daily control of body weight and
international normalized ratio self-test (in the Novacor group)
and twice-daily controls of temperature, blood pressure, and
pump output, as well as wound dressing changes according to
a special protocol. Patients underwent transplantation when
they reached New York Heart Association functional class I
without organ failure, except patients with uncontrolled
pocket infections and patients with major technical problems
(pump failure).
Definition of complications. A bleeding complication was
defined as blood loss of more than 1500 mL/m2 in 24 hours.
Major neurologic complications were defined as neurologic
deficits proved and differentiated by computed tomographic
scan. Infection definition included several parts: a pocket
infection was defined as being associated with local signs of
infection with purulent secretions necessitating lavage
drainage and with positive bacterial cultures. Criteria for
valved conduit endocarditis were signs of systemic infection
despite adequate antibiotic therapy, increased central venous
pressure, low pump output with a dilated left ventricle, and an
abnormal Doppler echocardiographic image above the inflow
cannula. The presence of a septic complication was indicated
by a body temperature above 38.5°C, white blood cell count
greater than 12,000 gm/dL, high output states, low systemic
vascular resistance, and positive blood cultures. Failure of the
right side of the heart was defined as a cardiac index less than
2.2 L · min–1 · m–2 despite a central venous pressure of 18 to
22 mm Hg and double-drug inotropic support in the absence
of high pulmonary vascular resistance. Arrhythmic complica-
tions were defined as hemodynamically relevant rhythm dis-
orders necessitating electrotherapy. The criterion for acute
renal failure was the necessity of renal replacement therapy
(hemofiltration or dialysis).
Statistical analysis. Statistical analysis of the data was
done with the SPSS software (SPSS for Windows, SPSS Inc,
Chicago, Ill). Variables are expressed as mean values with the
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SD. The specific tests applied for different analyses are
detailed below the respective tables.
Results
All patients survived the operation. Weaning from
extracorporeal circulation was successful in both
groups with the use of two positive inotropic agents
(dopamine, phosphodiesterase III inhibitors) except in
6 patients in the Novacor group and 5 patients in the
HeartMate group who required three inotropic agents
for support of the right side of the heart (dopamine, epi-
nephrine, phosphodiesterase III inhibitors) and in 1
patient of each group in whom failure of the right side
of the heart could only be managed by the institution of
an additional right ventricular assist device (Thoratec
plus Novacor, Medos plus HeartMate).
No statistically significant differences between the
groups were found with regard to postimplantation
hemodynamics (Table III), median postoperative venti-
latory support time (Novacor, 2 days, 25th and 75th
percentiles 1.5 and 3.2, respectively; HeartMate, 2.5
days, 25th and 75th percentile 1.5 and 4.0, respective-
ly), mean stay in the intensive care unit (Novacor, 16.7
± 15.5 days; HeartMate, 12.2 ± 8.7 days, P = .3), mean
duration of total hospitalization (Novacor, 55.6 ± 30.7
days; HeartMate, 58.6 ± 30.1 days, P = .8), and mean
duration of support (Novacor, 235.3 ± 210 days;
HeartMate, 174.6 ± 175 days, P = .4). Laboratory data
obtained on postoperative days 1, 7, 14, and 30 reflect-
ed good organ recovery without any statistically signif-
icant differences between the groups (Table V).
Fifteen patients (75%) supported with the Novacor
LVAS and 14 patients (70%) supported with the
HeartMate LVAS were able to be discharged from the
hospital to home while the device was in place, and 1
patient in the Novacor group was moved to a rehabili-
tation center because neurologic complications pre-
cluded home care. Ten patients in the Novacor group
and 9 in the HeartMate group had to be readmitted to
the hospital because of a variety of complications as
detailed in Table VI. Tables VII and VIII, which show
the general complications occurring during support,
indicate that patients in the Novacor group were read-
mitted mainly because of neurologic disorders whereas
in patients in the HeartMate group infections and tech-
nical problems were the main reasons. Five patients (3
Novacor, 2 HeartMate) were able to return to work.
Mean duration of out-of-hospital support was 241 ±
179 days (range 20-642 days) for patients in the
Novacor group and 166 ± 152 days (range 11-616
days) for patients in the HeartMate group (P = .14).
Of the Novacor group, 13 (65%) have undergone
transplantation and have left the hospital, 3 are still
awaiting transplantation, and 4 (20%) died while
receiving LVAS support (multiple organ failure/sepsis,
n = 3; massive thromboembolism, n = 1). Of the
HeartMate group, 12 (60%) have received a transplant,
2 are waiting, and 6 (30%) died while receiving LVAS
support (multiple organ failure and/or sepsis, n = 5;
cerebral bleeding, n = 1).
The prevalence of complications is detailed in Tables
VII and VIII. Four patients in the Novacor group and 2
in the HeartMate group were completely free of com-
plications during LVAS support.
Discussion
The Novacor LVAS and the TCI HeartMate VE
LVAS are comparable systems available for left ven-
tricular assistance, the efficacies of which have been
reported by many authors.2-9 In a comparative trial in
which all patients underwent the same procedures in
terms of surgical team, implantation technique, and
postoperative protocols, we tried to determine the dif-
ferences between the two devices.
As expected, hemodynamic outcome was compara-
ble in the two subsets of patients. Both groups had a
higher postoperative central venous pressure compared
with preoperative measurements possibly resulting
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Table I. Cause of heart failure
Novacor HeartMate 
(n = 20) (n = 20)
Idiopathic dilated cardiomyopathy 13 9
Ischemic cardiomyopathy 6 10
Fulminant myocarditis 1 -
Valvular heart disease - 1
χ2: P = .3.
Table II. Preoperative clinical blood chemistry values
Novacor HeartMate 
Parameter (mean) (mean) P value*
BUN (mg/dL) 82 ± 39 76 ± 37 .7
Creatinine (mg/dL) 1.5 ± 0.6 1.6 ± 0.6 .9
Bilirubin (mg/dL) 2.0 ± 1.0 1.7 ± 1.1 .3
AST (U/L) 34 ± 27 43 ± 69 .7
ALT (U/L) 46 ± 62 91 ± 190 .4
γ-GT (U/L) 101 ± 79 67 ± 45 .1
AP (U/L) 187 ± 129 147 ± 61 .3
Lipase (U/L) 123 ± 80 155 ± 79 .2
Amylase (U/L) 28 ± 38 23 ± 21 .7
WBC (gm/L) 8.0 ± 5.4 7.4 ± 5.5 .8
Platelets 203 ± 92 227 ± 127 .6
BUN, Blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; γ-GT, γ-glutamylcyclotransferase; AP, alkaline phos-
phatase; WBC, white blood cells.
*Unpaired t test.
from insufficiency of the right side of the heart, which
is a common problem after LVAD implantation, or
from a relative volume overload of the right side of the
heart. As reported by other authors,3,5,9 bleeding still
constitutes a problem after ventricular assist device
implantation. In our trial we found a similar prevalence
in both patient groups but a significantly higher amount
of blood loss in the Novacor collective, which might
result from the more aggressive anticoagulation proto-
col. The prevalence of reoperation because of bleeding
was similar between groups, with 6 patients in the
Novacor and 4 patients in the HeartMate groups. The
prevalence of bleeding noted in Table VIII included 3
cases of late bleeding (2 Novacor, 1 HeartMate) that
occurred after aspirin medication, which in our prima-
ry experience was given 4 to 5 days after the operation
after removal of chest drains, when the patient had been
moved to the regular care ward. We therefore have
changed our anticoagulation protocol and now start to
administer aspirin 2 weeks after the operation. Despite
the high amount of blood loss, this complication did not
impair patient outcome.
In accordance with the data reported by various other
authors,5,6,10 patients supported with the Novacor LVAS
showed a higher prevalence of neurologic disorders
despite the aggressive anticoagulation protocol.
Thromboembolic events were found in 4 patients and
occurred on postoperative days 14 to 67 (mean 29
days). However, in 2 of these patients, anticoagulation
was only suboptimal at the time of the event. It is high-
ly recommended that anticoagulation in patients with
the Novacor LVAS be carefully monitored and that
attention be paid to the optimal balance between a pos-
sible bleeding complication and the risk of thromboem-
bolism. One other explanation for the increased throm-
boembolic risk may be the configuration of the Novacor
inflow and outflow grafts, which have a diameter of 22
mm compared with 18 mm in the HeartMate device,
and the longer inflow graft, which might favor the
development of thrombi. Cerebral bleeding was found
in 1 patient of each cohort and resulted from a decom-
pensated coagulation because of a septic attack. These
results show that from the neurologic point of view, the
HeartMate device is superior to the Novacor system.
In contrast, the number of patients who had system-
related infections, which occurred on postoperative
days 30 to 111 (mean 58 days), was significantly high-
er in association with the HeartMate LVAS, although
implantation was done by the same surgical team and
the same antibiotic protocols and wound care manage-
ment were applied. It is suggested that because of the
rotary movement of the pump there is an increased
reaction between the pump housing and the surround-
ing tissue, leading to an increased secretion involving a
higher risk of infection. To reduce device infection, we
have modified our technique of implanting HeartMate
devices.11 Conduit endocarditis was found in 3
patients, 1 of whom had both Novacor and Thoratec
support and in whom both inflow and outflow conduits
were replaced. This patient underwent cardiac trans-
plantation later and survived. The other 2 cases of con-
duit endocarditis occurred in 2 patients in the
HeartMate group: in 1 case it was discovered at autop-
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Table III. Preoperative and postoperative hemodynamic variables
Preop Postop
Variable Novacor (mean) HeartMate (mean) P value* Novacor (mean) HeartMate (mean) P value*
CI (L · min–1 · m–2) 2.1 ± 0.4 2.1 ± 0.4 .9 2.9 ± 0.4 3.0 ± 0.6 .8
mPAP (mm Hg) 39 ± 7 38 ± 8 .7 30 ± 7 28 ± 5 .3
mCVP (mm Hg) 13 ± 6 14 ± 7 .9 16 ± 4 15 ± 3 .5
PVR (dyn · min · cm–5) 281 ± 138 229 ± 91 .2 249 ± 72 236 ± 69 .6
SVR (dyn · min · cm–5) 1187 ± 413 1018 ± 289 .2 795 ± 255 804 ± 135 .9
mPC (mm Hg) 24 ± 8 22 ± 9 .5 11 ± 4 9 ± 4 .1
Postop indicates value on admission to the intensive care unit. CI, Cardiac index; mPAP, mean pulmonary artery pressure; mCVP, mean central venous pressure; PVR,
peripheral vascular resistance; SVR, systemic vascular resistance; mPC, mean pulmonary capillary wedge pressure.
*Unpaired t test.
Table IV. Preoperative risk factors
Risk factor Novacor HeartMate P value*
Inotropic support 20 20 1
(at least 2 drugs)
IABP 7 6 .7
Reoperation 3 2 .6
Renal failure 4 4 1
AICD 2 1 .5
IABP, Intra-aortic balloon pump; AICD, automatic implantable cardioverter-
defibrillator.
*χ2 test.
sy and in the other case the patient subsequently under-
went transplantation and survived. Pocket infections
could usually be managed by local irrigation. If signs
of systemic infection become obvious, antibiotics are
given for at least 4 weeks. Two patients with pocket
infection died during support, 1 of sepsis (HeartMate)
and 1 of massive thromboembolism (Novacor). The
systemic infections were mainly episodes of infections
with positive cultures revealing the same pathogens
obtained from the pocket or driveline.
In terms of reliability, the HeartMate device com-
pared badly with the Novacor LVAS. Minor problems
were controller exchanges, which were a result of soft-
ware faults and after some modification were eliminat-
ed. Driveline cracks in both groups were associated
with an extended duration of support (>300 days) and
were found in very active patients putting major stress
on the material. The cracks could be sealed without haz-
ard to the patient. Unfortunately, all pump failures at
this institution in our total HeartMate VE LVAS collec-
tive (n = 27) occurred in the current study population. In
1 patient, who was mobile on the regular care ward,
pump failure occurred 8 weeks after implantation
because of fluid in the motor component. The nature of
the fluid was the subject of controversy between the
manufacturer and us. According to their statement, the
fluid had a red-brown appearance, but it was not ana-
lyzed with regard to heme. In the second patient, pump
failure happened at home after 14 months of support.
This patient was admitted to the hospital on an emer-
gency basis and received support with the pneumatic
system before undergoing exchange of the pump and
being discharged from the hospital to his home again,
where he is still waiting for cardiac transplantation. On
examination, minor cracks were found in the mem-
brane, which made the transition of blood into the motor
chamber possible, thus causing a standstill. In another
case occurring after 2 months of support the failure was
patient related and resulted from a disconnected infu-
sion cannula with blood leaking into the pump filter and
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Table V. Postoperative clinical blood chemistry values
Novacor (mean) HeartMate (mean)
Parameter POD 1 POD 7 POD 14 POD 30 POD 1 POD 7 POD 14 POD 30 P values*
BUN (mg/dL) 74.4 ± 30.3 65.6 ± 45.4 42.0 ± 24.6 43.8 ± 41.4 71.6 ± 24.6 72.3 ± 46.9 54.0 ± 34.6 45.5 ± 15.8 .3
Creatinine 1.6 ± 0.7 1.1 ± 0.5 0.9 ± 0.4 1.0 ± 0.4 1.5 ± 0.5 1.2 ± 0.6 1.2 ± 0.6 1.0 ± 0.3 .1
(mg/dL)
Bilirubin 3.0 ± 1.6 4.5 ± 4.6 3.9 ± 3.8 3.2 ± 5.2 3.1 ± 1.9 4.7 ± 6.3 9.2 ± 15.5 2.9 ± 6.4 .8
(mg/dL)
AST (U/L) 60.4 ± 35.3 34.5 ± 20.3 36.1 ± 26.7 23.1 ± 9.6 62.1 ± 59.2 34.5 ± 20.3 31.9 ± 23.1 24.4 ± 26.2 .9
ALT (U/L) 32.0 ± 35.1 20.7 ± 18.9 24.1 ± 22.6 18.7 ± 11.0 46.1 ± 73.2 18.7 ± 14.3 29.6 ± 27.5 21.9 ± 27.0 .5
γ-GT (U/L) 35.8 ± 23.7 143.4 ± 123.2 141.7 ± 112.7 105.0 ± 79.0 27.5 ± 17.8 76.2 ± 47.7 89.3 ± 63.7 104.4 ± 75.2 .5
AP (U/L) 99.7 ± 17.8 262.2 ± 173.4 275.3 ± 139.3 281.8 ± 148.8 95.6 ± 23.2 202.2 ± 111.4 244.8 ± 125.1 285.6 ± 148.1 .8
Lipase (U/L) 154.5 ± 89.2 212.0 ± 128.1 213.2 ± 157.6 277.1 ± 112.0 152.3 ± 162.4 198.1 ± 101.5 342.3 ± 252.9 208.2 ± 142.9 .4
Amylase 30.7 ± 31.2 31.7 ± 16.1 24.0 ± 15.1 35.9 ± 19.5 27.9 ± 28.5 22.7 ± 15.2 37.7 ± 26.6 22.9 ± 12.9 .8
(U/L)
WBC (gm/L) 7.9 ± 6.4 9.8 ± 6.4 14.6 ± 14.0 7.1 ± 2.5 6.7 ± 6.0 7.8 ± 5.8 9.4 ± 5.8 5.3 ± 1.9 .9
Platelets 115.9 ± 64.6 137.8 ± 64.1 273.0 ± 134.8 357.9 ± 176.8 124.4 ± 47.1 134.1 ± 68.5 261.4 ± 169.4 255.5 ± 116.6 .9
Abbreviations same as for Table II.
*GLM (general linear model for repeated measures).
Table VI. Causes for readmission of out-of-hospital patients (several causes per patient possible)
Complication Novacor (n = 10) Event/patient mo HeartMate (n = 9) Event/patient mo P value*
Neurologic 5 0.042 (0.006-0.078) 1 0.013 (–0.012-0.038) .4
Driveline infection 2 0.017 (–0.006-0.04) 1 0.013 (–0.012-0.038) 1
Pocket infection 2 0.017 (–0.006-04) 5 0.065 (0.01-0.12) .1
Technical 1 0.008 (–0.008-0.024) 3 0.039 (–0.004-0.082) .3
Gastrointestinal tract 1 0.008 (–0.008-0.024) - 0.013 (–0.012-0.038)
Miscellaneous 1 0.008 (–0.008-0.024) 1
Linearized rates of complications are calculated as the number of complications per patient month in a given time frame (95% confidence limits).
*Fisher exact test.
causing the failure. The patient was immediately
switched to support with the pneumatic system. He died
later of multiple organ failure and sepsis. The fourth
patient was at home as well when pump failure
occurred. He was admitted to the intensive care unit
immediately and support was switched to the pneumat-
ic console before the patient underwent heart transplan-
tation. It was determined that the electronic commutator
was malfunctioning, probably because of static dis-
charge, so that it only operated at its fallback position,
which is basal rate. Subsequently, all existing pumps
were protected with the TCI-provided Static Protect
Adaptor.
Apart from the patient-related failure, we had 3
device-related failures of the HeartMate VE LVAS in a
total of 27 patients (11%) compared with no pump fail-
ures in a total of 76 patients supported with the
Novacor device at our center. In accordance with the
findings of McCarthy and colleagues,3 infection and
reliability of this device are major problems and still
have to be addressed.
Gastrointestinal tract complications comprised mesen-
teric ischemia, cholecystectomy, pancreatitis, and ileus.
Despite the multimorbidity and the hopeless situation
of the patients before device implantation, most of them
had organ recovery with support and a considerable
number of patients in both groups could be discharged
from the hospital to await cardiac transplantation at
home. Some of these patients were even able to return
to work, which added to their quality of life. The results
achieved are promising regardless of the complications.
Both devices are undergoing revisions to address the
current problems, that is, the thromboembolism associ-
ated with the Novacor LVAS and the infection and reli-
ability problems found in the HeartMate device. If the
devices can be successfully improved in these terms, the
application of implantable LVADs should be considered
as an alternative to cardiac transplantation.
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Discussion
Dr Verdi J. DiSesa (Chicago, Ill). You certainly have had
more frequent technical failures with the HeartMate than we
have seen. I would still maintain that avoiding anticoagula-
tion and neurologic events has some advantages even if the
device must be changed, although perhaps some of the new
software and the new techniques you are using can obviate
that.
Dr Edward B. Savage (Chicago, Ill). This represents a
nice comparative series, and you have a large experience with
these devices. I am concerned about the conclusions drawn in
your abstract. Both of these devices were in the development
phase during your protocol and they have undergone many
changes, which you have outlined. To conclude that one
device might be superior to another is a little premature, par-
ticularly since many of the device deficiencies that you cited
have been addressed.
Dr DiSesa. Would you care to respond?
Dr El-Banayosy. I think no response is needed.
Dr DiSesa. Are you continuing to use both devices?
Dr El-Banayosy. Yes, we are continuing to use both of the
devices. What we are trying to do now is select patients for
the two devices by estimating the levels of proteins C and S
before implantation of the devices. Patients having abnormal
levels of these proteins are supported with the HeartMate
device, and patients with normal levels receive the Novacor
device. That is what we are trying to do, but I have no data as
yet from this new study.
Dr Thierry G. Mesana (Marseille, France). You men-
tioned that most of the thromboembolic accidents occurred at
a certain period with the Novacor device and occurred main-
ly with the Novacor LVAS. Did you observe at the same time
some specific biologic modifications to explain that, such as
inflammatory response or higher parameters?
Dr El-Banayosy. The incidence of the four major neuro-
logic complications was independent of the inflammatory
response in these patients. However, in 2 of our patients, anti-
coagulation was suboptimal at the time of the event.
Dr Boulos Asfour (Muenster, Germany). I have a question
regarding the thromboembolism you had and the anticoagu-
lation. Did the neurologic complications in the Novacor pop-
ulation occur early? I ask this because you mentioned that
you also had more blood loss in the Novacor group. My guess
is you do the same as we do in these patients: begin adminis-
tration of anticoagulants rather late when you remove the
chest tubes and not before.
Dr El-Banayosy. In the past we started aspirin administra-
tion on the fourth or fifth postoperative day after removal of
chest drains and that is why we had more bleeding in these
patients. We have now changed our strategy and we give
aspirin beginning on postoperative day 14.
Dr Asfour. You said you had more bleeding because of
aspirin, but now you say that you start rather late. Was the
therapy begun at the time the chest tubes were removed?
Dr El-Banayosy. Yes.
Dr Asfour. When did you find these neurologic complica-
tions? Were there early complications in the intensive care
unit before the start of aspirin therapy or were the complica-
tions late?
Dr El-Banayosy. They occurred during aspirin and war-
farin (Coumadin) therapy.
Dr Asfour. They were late, not in the intensive care unit?
Dr El-Banayosy. Later, yes. I mentioned that these com-
plications happened between postoperative days 14 and 67,
and the mean was 29 days.
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